Program
SHR-1918
A development code. Also written as “SHR-1918 injection set” and “SHR-1918 Injection”.
In Jiangsu HengRui Medicine's pipeline, ANGPTL3
. Its studies are mostly in Homozygous Familial Hypercholesterolemia · Hyperlipidemias · Hypertriglyceridemia · Hypercholesterolemia, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 85 open or running | phase 3since Dec 4, 2024 | Jun 21, 2022 | Jun 2027phase 2 · NCT07308392 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-1918
, phase 4, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 21, 2022First study: phase 1 study in HyperlipidemiasFirst studyNCT05432544 · 72 enrolled · China
- Aug 15, 2023Phase 2 study in Homozygous Familial HypercholesterolemiaNCT06009393 · 26 enrolled · China
- Oct 26, 2023Phase 2 study in HyperlipidemicNCT06109831 · 335 enrolled · China
- Dec 4, 2024Phase 3 study in Homozygous Familial HypercholesterolemiaNCT06723652 · 55 enrolled · China
- Aug 14, 2025Phase 2 study in Homozygous Familial HypercholesterolemiaNCT07133815 · 55 planned · China
- Sep 22, 2025Phase 3 study in HyperlipidemiasNCT07230730 · 900 planned · China
- Dec 15, 2025Phase 2 study in Severe Hypertriglyceridemia With a High Risk of Acute PancreatitisNCT07308392 · 119 enrolled · China
- Feb 5, 2026Phase 3 study in HypercholesterolemiaNCT07404553 · 126 planned · China
Ahead
- Jun 2027Primary completion: phase 2 study in Severe Hypertriglyceridemia With a High Risk of Acute PancreatitisNCT07308392
- Oct 2027Primary completion: phase 3 study in HyperlipidemiasNCT07230730
- Jul 2028Primary completion: phase 3 study in HypercholesterolemiaNCT07404553
TargetBeta
“ANGPTL3”the company's pipeline, read by Claude · source
Other programs on ANGPTL3
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07404553Hypercholesterolemia · China | 3 | Recruiting | Jul 2028 | 126 |
| NCT07308392Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis · China | 2 | Active, not recruiting | Jun 2027 | 119 |
| NCT07230730Hyperlipidemias · China | 3 | Recruiting | Oct 2027 | 900 |
| NCT07133815Homozygous Familial Hypercholesterolemia · China | 2 | Not yet recruiting | Dec 2025 | 55 |
| NCT06723652Homozygous Familial Hypercholesterolemia · China | 3 | Completed | Aug 25, 2025 | 55 |
| NCT06109831Hyperlipidemic · China | 2 | Completed | Jul 4, 2025 | 335 |
| NCT06009393Homozygous Familial Hypercholesterolemia · China | 2 | Completed | Jun 29, 2024 | 26 |
| NCT05432544Hyperlipidemias · China | 1 | Active, not recruiting | Dec 11, 2023 | 72 |
How it is read
Names in the registry
- “SHR-1918”, 6 entries
- “SHR-1918 injection set”, 1 entry
- “SHR-1918 Injection”, 1 entry
Codes read as this program: SHR1918.
Conditions, from the studies’ own filings
- Homozygous Familial Hypercholesterolemia, 3 studies
- Hyperlipidemias, 2 studies
- Hypertriglyceridemia, 1 study
- Hypercholesterolemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.